secwatch.observer — SEC 8-K summary
======================================

Issuer:     SUPERNUS PHARMACEUTICALS, INC. (SUPN)
CIK:        0001356576
Form:       8-K
Filed at:   2026-04-07T23:59:59+00:00
Accession:  0001104659-26-040497
Event type: m_and_a
Sentiment:  neutral
Materiality: 0.65
Item codes: 1.01, 2.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Supernus acquires NV-5138/SPN-820 assets from Navitor; up to $350M in milestones
--------------------------------------------------------------------------------

- Supernus buys all IP, inventory, and regulatory materials for CNS compound NV-5138 (SPN-820).
- Consideration: complete a Phase 2b study plus milestone payments up to $350M tied to development, regulatory, and commercial goals.
- No upfront cash; Supernus may stop pursuing milestones if Phase 2b study fails in its sole discretion.
- Agreement includes five-year post-closing non-compete and non-solicitation covenants for Navitor parties.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1356576/000110465926040497/0001104659-26-040497-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1356576/000110465926040497/tm2611273d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-26-040497

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer